ID: h-9d2bca0f28
Hypothesis
Combined p-tau217 + p-tau231 Panel Increases Specificity for Treatment Cessation Determination
p-tau231 reflects earlier amyloid-driven changes in entorhinal cortex while p-tau217 reflects downstream neuronal involvement.
EvidencePending (0%)📖 7 cit🗣 1 debates✓ 7 support✗ 2 oppose
⚠ Orphaned Senate Quality Gates →
🧪 Overview
p-tau231 reflects earlier amyloid-driven changes in entorhinal cortex while p-tau217 reflects downstream neuronal involvement. The combination captures the full spectrum of amyloid-to-tau propagation resolution. However, the composite algorithm is not operationally defined, weighting schemes are unspecified, and temporal window evidence from natural disease course may not transfer to treatment kinetics. Addition of p-tau231 may increase assay complexity without proportional predictive gain.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["APP Full Length<br/>Membrane Protein"]
B["BACE1 Beta-Secretase<br/>Cleavage at beta-site"]
C["sAPPbeta + CTFbeta<br/>C-terminal Fragment"]
D["Gamma-Secretase Complex<br/>PSEN1/PSEN2"]
E["Abeta42 Peptide<br/>Amyloidogenic Fragment"]
F["Abeta Oligomers<br/>Toxic Aggregates"]
G["Amyloid Plaques<br/>Extracellular Deposits"]
H["ADAM10 Alpha-Secretase<br/>Non-amyloidogenic Path"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
A --> H
H -.->|"competes with BACE1"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix7 supports2 contradicts
Supports
Combination of plasma p-tau217/p-tau231 ratio improves discrimination of amyloid status
Supports
Clustering of Tau fibrils impairs the synaptic composition of α3-Na(+)/K(+)-ATPase and AMPA receptors.
Supports
Mutant Tau protein-induced abnormalities in the Na(+)-dependent glutamine translocation and recycling and their impact on astrocyte-neuron integrity in vitro.
Supports
Cell biology and dynamics of Neuronal Na(+)/K(+)-ATPase in health and diseases.
Supports
Disease-specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease.
Supports
Biophysical characterization of the Varroa destructor Na(V)1 sodium channel and its affinity for τ-fluvalinate insecticide.
Contradicts
Combination improves amyloid status discrimination, not treatment cessation outcomes
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — NA
No curated PDB or AlphaFold mapping for NA yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NA - Multi-biomarker diagnostic.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Medium
0.0429
Events (7d)
1
Price History
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF plasma p-tau231 normalizes before p-tau217 in participants who stop anti-amyloid treatment due to biomarker normalization, THEN the p-tau231 normalization will occur within 3 months of treatment ce | Mean p-tau231 return to baseline/normal levels by month 21 post-treatment cessation; mean p-tau217 return to baseline by month 27 or later | — no observation — | pending | 0.28 |
| IF p-tau231 is added to a p-tau217-only biomarker panel in a randomized controlled trial of anti-amyloid therapy, THEN the composite panel will achieve ≥15% higher specificity (90% vs 75%) for determi | Specificity for treatment cessation determination ≥90% with dual-marker algorithm vs 75% with p-tau217 alone | — no observation — | pending | 0.35 |
🔮 Falsifiable Predictions (2)
pendingconf 35%
IF p-tau231 is added to a p-tau217-only biomarker panel in a randomized controlled trial of anti-amyloid therapy, THEN the composite panel will achieve ≥15% higher specificity (90% vs 75%) for determining treatment cessation at 18 months post-baseline, compared to p-tau217 alone.
Predicted outcome: Specificity for treatment cessation determination ≥90% with dual-marker algorithm vs 75% with p-tau217 alone
Falsification: Specificity with p-tau231+p-tau217 composite does not exceed p-tau217 alone specificity by ≥15 percentage points; any panel combining both markers yields <90% specificity for treatment cessation
pendingconf 28%
IF plasma p-tau231 normalizes before p-tau217 in participants who stop anti-amyloid treatment due to biomarker normalization, THEN the p-tau231 normalization will occur within 3 months of treatment cessation while p-tau217 will lag by ≥6 additional months, indicating separable temporal dynamics.
Predicted outcome: Mean p-tau231 return to baseline/normal levels by month 21 post-treatment cessation; mean p-tau217 return to baseline by month 27 or later
Falsification: Both biomarkers normalize within 3 months of each other (overlapping 95% CI), indicating redundant temporal windows and no added specificity from p-tau231; OR p-tau231 normalization occurs after p-tau
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.